Seagen shared that the company’s Phase III trial of Adcetris (brentuximab vedotin) demonstrated significant improvements in the overall survival of patients diagnosed with advanced classical Hodgkin lymphoma.

Merck’s Keytruda (pembrolizumab) received a rejection from the U.S. Food and Drug Administration for each of six supplemental Biologics License Applications to update the dosing frequency of the checkpoint inhibitor to include every-six-weeks administration.

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.